Xbrane Biopharma AB Company Description

Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars.

The company offers Ximluci, a ranibizumab biosimilar used for the treatment of wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults.

Its pre-clinical phase products include BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis, Crohn’s disease, and axial spondylitis; Xdivane, a nivolumab biosimilar candidate, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; and Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma.

The company was incorporated in 2008 and is headquartered in Solna, Sweden.

Xbrane Biopharma AB (publ)

Country	Sweden
Founded	2008
Industry	Biotechnology
Sector	Healthcare
Employees	93
CEO	Martin Amark

Contact Details

Address: Retzius vAeg 8 Solna, 171 65 Sweden
Phone	46 8 55 90 56 00
Website	xbrane.com

Stock Details

Ticker Symbol	XBRANE
Exchange	Nasdaq Stockholm
Fiscal Year	January - December
Reporting Currency	SEK
ISIN Number	SE0007789409
SIC Code	2836

Key Executives

Name	Position
Siavash Bashiri	Chief Operating Officer, Head of Biosimilars and Deputy Chief Executive Officer
Martin Amark	Chief Executive Officer
Associate Prof. Jan-Willem De Gier	Co-Founder
Dr. Samuel Wagner Ph.D.	Co-Founder and Member of Scientific Advisory Board
Anette Lindqvist	Chief Financial Officer and Head of Investor Relations
Dr. David Vikström	Chief Technology Officer
Dina Jurman	Head of Clinical Affairs
Anders Wallström	Head of Manufacturing and Supply Chain
Håkan Yildirim	Head of Intellectual Property